Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLAU | P00749 | 20/20 | 1.00 |
| ▸ | PLG | P00747 | 13/20 | 1.00 |
| ▸ | KLK1 | P06870 | 12/20 | 1.00 |
| ▸ | PLAT | P00750 | 11/20 | 1.00 |
| ▸ | F2 | P00734 | 9/20 | 1.00 |
| ▸ | PRSS1 | P07477 | 9/20 | 1.00 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL7352867 | 0.95 | PLAU (0.90) | PLAUPLGKLK1PLATF2 | |
| SCHEMBL6439559 | 0.89 | PLAU (0.86) | PLAUPLGKLK1PLATF2 | |
| SCHEMBL4320529 | 0.89 | PLAU (1.00) | PLAUPLGKLK1PLATF2 | |
| SCHEMBL7339552 | 0.88 | PLAU (0.81) | PLAUPLGKLK1PLATF2 | |
| SCHEMBL7341506 | 0.88 | PLAU (0.81) | PLAUPLGKLK1PLATF2 | |
| Trifluoroacetic Acid SCHEMBL7336462 | 0.86 | PLAU (0.90) | PLAUPLGKLK1PLATF2 | |
| SCHEMBL7854503 | 0.84 | PLAU (0.72) | PLAUPLGKLK1PLATF2 | |
| SCHEMBL7352771 | 0.81 | PLAU (0.70) | PLAUPLGKLK1PLATF2 | |
| SCHEMBL6436165 | 0.81 | PLAU (0.67) | PLAUPLGKLK1PLATF2 | |
| SCHEMBL7358951 | 0.78 | PLAU (0.67) | PLAUPLGKLK1PLATF2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1063975-B1 | CROSSLINKABLE MACROMERS BEARING INITIATOR GROUPS | SURMODICS INC (US) | 2005-05-18 | — | — | EP | claimed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | claimed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | claimed |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | DACK KEVIN NEIL (GB) | 2005-02-03 | — | — | US | disclosed |
| US-20030199440-A1 | Composition for the treatment of damaged tissue | PFIZER INC. | 2003-10-23 | — | — | US | disclosed |
| EP-1242120-A2 | COMBINATIONS OF GROWTH FACTORS AND I:UPA OR I:MMP FOR THE TREATMENT OF DAMAGED TISSUE | Pfizer Limited (GB) | 2002-09-25 | — | — | EP | disclosed |
| US-20010049374-A1 | Urokinase inhibitors | STEELE ANDREW W (US) | 2001-12-06 | — | — | US | disclosed |
| US-6284796-B1 | NAPHTHAMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-09-04 | — | — | US | disclosed |
| WO-2001049309-A2 | COMBINATIONS OF GROWTH FACTORS AND I: UPA OR I: MMP FOR THE TREATMENT OF DAMAGED TISSUE | PFIZER LIMITED (GB) | 2001-07-12 | — | — | WO | disclosed |
| US-6258822-B1 | ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS | ABBOTT LABORATORIES | 2001-07-10 | — | — | US | disclosed |
| EP-1000018-A2 | UROKINASE INHIBITORS | Abbott Laboratories (US) | 2000-05-17 | — | — | EP | disclosed |
| WO-1999005096-A2 | UROKINASE INHIBITORS | ABBOTT LABORATORIES (US) | 1999-02-04 | — | — | WO | disclosed |
| EP-0377191-B1 | Radiation-sensitive ethylenically unsaturated copolymerisable compounds, and process for their preparation | BASF AG (DE) | 1994-03-23 | — | — | EP | disclosed |
| EP-0499836-A2 | Carbonate and carbonyl-containing compounds, their preparation and applications | BASF Aktiengesellschaft (DE) | 1992-08-26 | — | — | EP | disclosed |
| EP-0377191-A2 | Radiation-sensitive ethylenically unsaturated copolymerisable compounds, and process for their preparation | BASF Aktiengesellschaft (DE) | 1990-07-11 | — | — | EP | disclosed |
| EP-0377198-A2 | Chloroformiates of aromatic ketones, and process for their preparation | BASF Aktiengesellschaft (DE) | 1990-07-11 | — | — | EP | disclosed |
| EP-0281941-A2 | Coreactive photoinitiators | CIBA-GEIGY AG (CH) | 1988-09-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199440-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885PLG 33/4885KLK1 613/4885 |
| US-20050026836-A1 | Composition for the treatment of damaged tissue | MMP1, SERPINE1, COL14A1 | PLAU 119/4885PLG 33/4885KLK1 613/4885 |
| US-20010049374-A1 | Urokinase inhibitors | SERPINE1, PLAU, SERPINB1 | PLAU 2/4885PLG 10/4885KLK1 62/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.